Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iberdomide hydrochloride by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Multiple Myeloma. According to...
Iberdomide hydrochloride by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to...
Iberdomide hydrochloride by Bristol-Myers Squibb for Refractory Multiple Myeloma: Likelihood of Approval
Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Refractory Multiple Myeloma. According to...
Iberdomide hydrochloride by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Iberdomide hydrochloride?
Iberdomide hydrochloride is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Multiple Myeloma (Kahler...